Management of Intermediate Trabecular Bone Score (TBS 1200‑1350)
Initial Assessment
- Measure bone mineral density (BMD) by dual‑energy X‑ray absorptiometry (DXA) at the lumbar spine, femoral neck, and total hip to obtain T‑scores. 1
- Perform vertebral fracture assessment (VFA) or spinal radiographs because 21 %–25.5 % of individuals with normal BMD but degraded TBS have asymptomatic vertebral fractures. 3
- Screen for secondary causes of osteoporosis (e.g., diabetes, hyperparathyroidism, glucocorticoid excess, renal insufficiency, inflammatory disease, and osteoporosis‑inducing medications). [1][4]
Pharmacologic Intervention Thresholds
- Initiate anti‑osteoporotic therapy when any of the following are present:
First‑Line Pharmacologic Options (Moderate Fracture Risk)
- Oral bisphosphonates are recommended as initial therapy:
Second‑Line Pharmacologic Options (Oral Intolerance, Malabsorption, Non‑adherence)
- Intravenous zoledronate 5 mg annually. [6][8]
- Subcutaneous denosumab 60 mg every 6 months. [6][1]
Anabolic Therapy (High Fracture Risk)
- Anabolic agents are preferred first‑line when any of the following are met:
- Recommended anabolic agents: teriparatide or romosozumab, followed by sequential anti‑resorptive therapy to prevent bone loss rebound. [5][7]
Non‑Pharmacologic Measures (All Patients)
- Calcium intake 1,000‑1,200 mg/day from diet and supplements as needed. [6][1]
- Vitamin D 800‑1,000 IU/day to achieve serum 25(OH)D > 32 ng/mL. [6][1]10
- Combined exercise program (balance training, resistance, endurance, and stretching) to lower fall risk. [1][5]
- Smoking cessation and moderation of alcohol consumption. [6][1]
Monitoring and Follow‑up
Repeat DXA with TBS assessment:
TBS is useful for monitoring response to anabolic agents (teriparatide, romosozumab) and long‑term denosumab, but not for bisphosphonate therapy because changes are minimal and not predictive of fracture risk reduction. 5
Bone turnover biochemical markers can be employed to assess adherence to anti‑resorptive therapy. 5
Technical Considerations for TBS
- Valid TBS measurement is limited to patients with body‑mass index 15‑37 kg/m²; the TBS 4.0 algorithm with direct soft‑tissue thickness correction expands this range. 3
- The least‑significant change (LSC) for TBS is 5.8 %. 3
Adherence
- Up to 64 % of men discontinue bisphosphonate therapy within 12 months, highlighting the need for patient education, counseling, and close monitoring. 5